|
rs1136410
|
|
Primary malignant neoplasm of lung
|
|
0.020 |
GeneticVariation
|
BEFREE |
We investigated associations between the risk of lung cancer in residents of the coal-mining region and polymorphisms in the genes APEX1 (rs1130409), hOGG1 (rs1052133), XRCC1 (rs25489, rs25487), XRCC2 (rs3218536), XRCC3 (rs861539), ADPRT/PARP1 (rs1136410), XPD/ERCC2 (rs13181), XPG/ERCC5 (rs17655), XPC (rs2228001), ATM (rs1801516), and NBS1 (rs1805794).
|
31584889 |
2019 |
|
rs3218536
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated associations between the risk of lung cancer in residents of the coal-mining region and polymorphisms in the genes APEX1 (rs1130409), hOGG1 (rs1052133), XRCC1 (rs25489, rs25487), XRCC2 (rs3218536), XRCC3 (rs861539), ADPRT/PARP1 (rs1136410), XPD/ERCC2 (rs13181), XPG/ERCC5 (rs17655), XPC (rs2228001), ATM (rs1801516), and NBS1 (rs1805794).
|
31584889 |
2019 |
|
rs1801516
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
We investigated associations between the risk of lung cancer in residents of the coal-mining region and polymorphisms in the genes APEX1 (rs1130409), hOGG1 (rs1052133), XRCC1 (rs25489, rs25487), XRCC2 (rs3218536), XRCC3 (rs861539), ADPRT/PARP1 (rs1136410), XPD/ERCC2 (rs13181), XPG/ERCC5 (rs17655), XPC (rs2228001), ATM (rs1801516), and NBS1 (rs1805794).
|
31584889 |
2019 |
|
rs3816360
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
After Bonferroni correction, rs3816360 and rs2290035 were evidently associated with lung cancer risk.
|
31580742 |
2019 |
|
rs3816358
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, rs3816358 polymorphism was not significantly associated with lung cancer risk.
|
31580742 |
2019 |
|
rs2290035
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
After Bonferroni correction, rs3816360 and rs2290035 were evidently associated with lung cancer risk.
|
31580742 |
2019 |
|
rs738792
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Similarly, there was no association between rs2267029, rs738792 or rs28382575 and lung cancer risk.
|
31570432 |
2019 |
|
rs738791
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
The allelic analysis showed that the rs738791 T allele did not confer lung cancer risk compared with the C allele.
|
31570432 |
2019 |
|
rs28382575
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Similarly, there was no association between rs2267029, rs738792 or rs28382575 and lung cancer risk.
|
31570432 |
2019 |
|
rs2267029
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Similarly, there was no association between rs2267029, rs738792 or rs28382575 and lung cancer risk.
|
31570432 |
2019 |
|
rs121434568
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
rs1057519848
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
rs1057519847
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
The identification of activating mutations in the epidermal growth factor receptor (EGFR) gene (deletions in exon 19 [Del19] and point mutation L858R in exon 21) has been the first important step toward molecularly guided precision therapy in lung cancer.
|
31564835 |
2019 |
|
rs3817963
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
There were significant joint effects of rs2395185 and rs3817963 with daily cooking duration on lung cancer incidence.
|
31557604 |
2019 |
|
rs2395185
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
There were significant joint effects of rs2395185 and rs3817963 with daily cooking duration on lung cancer incidence.
|
31557604 |
2019 |
|
rs4919510
|
|
Primary malignant neoplasm of lung
|
|
0.050 |
GeneticVariation
|
BEFREE |
A total of 37 patients with non-small cell lung cancer (NSCLC) were selected to determine the expression levels of miR-608; 96 NSCLC patients and 136 cancer-free healthy controls were recruited to determine the incidence of miR-608 rs4919510 in lung cancer patients.
|
31552102 |
2019 |
|
rs121434568
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
rs1057519848
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
rs1057519847
|
|
Primary malignant neoplasm of lung
|
|
0.100 |
GeneticVariation
|
BEFREE |
Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication.
|
31550632 |
2019 |
|
rs121917738
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Surfactant protein A2 mutations (G231V and F198S) have been identified to be associated with pulmonary fibrosis and lung cancer, and these mutations cause protein aggregation, instability as well as secretion deficiency.
|
31546020 |
2019 |
|
rs121917737
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Surfactant protein A2 mutations (G231V and F198S) have been identified to be associated with pulmonary fibrosis and lung cancer, and these mutations cause protein aggregation, instability as well as secretion deficiency.
|
31546020 |
2019 |
|
rs121913530
|
|
Primary malignant neoplasm of lung
|
|
0.070 |
GeneticVariation
|
BEFREE |
Adding mTOR and IGF1R inhibitors to ARS-1620 greatly improves its effectiveness on KRAS-G12C mutant lung cancer cells in vitro and in mouse models.
|
31534020 |
2019 |
|
rs884225
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Haplotype analysis of rs2233947 and rs884225 showed that the AA haplotype was associated with a significantly decreased risk of lung cancer (P<0.01).
|
31518089 |
2019 |
|
rs2293347
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Compared with the rs2293347 GG genotype, the AA/AG genotypes were associated with a significantly decreased risk of lung cancer (adjusted OR = 0.28, 95% confidence interval [CI]=0.13-0.61, P<0.01).
|
31518089 |
2019 |
|
rs2233947
|
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
The data presented in the current study support a protective role for the rs2233947 A allele against the development of lung cancer</span>.
|
31518089 |
2019 |